Fujimasa Tada

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2022 · 123 citations · Full text

Oncology, Hepatology, Medicine +8

Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma

Fujimasa Tada, Masanori Abe, Masashi Hirooka et al. · International Journal of Oncology · 2012 · 117 citations · Full text

Phase I/ii Study, Immunology, Immunoediting +25

Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases

Hironori Ochi, Masashi Hirooka, Yohei Koizumi et al. · Hepatology · 2012 · 108 citations · Full text

Predictors of hepatocellular carcinoma occurrence after direct‐acting antiviral therapy in patients with hepatitis C virus infection

Takao Watanabe, Yoshio Tokumoto, Kouji Joko et al. · Hepatology Research · 2018 · 72 citations

B cell-activating factor is associated with the histological severity of nonalcoholic fatty liver disease

Teruki Miyake, Masanori Abe, Yoshio Tokumoto et al. · Hepatology International · 2012 · 57 citations

Immunology, Pathology, Fatty Liver Disease +19